Michael Stek

724 total citations
17 papers, 557 citations indexed

About

Michael Stek is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Michael Stek has authored 17 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 11 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Michael Stek's work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (4 papers). Michael Stek is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (4 papers). Michael Stek collaborates with scholars based in United States, Netherlands and Thailand. Michael Stek's co-authors include Peter Reiss, Mary Bouxsein, Kenneth G. Faulkner, Mary E. Melton, Susan L. Greenspan, Paul DeLucca, David M. Burger, Eric Orwoll, James H. Clair and Joep M. A. Lange and has published in prestigious journals such as The Journal of Infectious Diseases, Journal of Bone and Mineral Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

Michael Stek

17 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Stek United States 12 318 178 146 140 73 17 557
Lidia Gazzola Italy 13 384 1.2× 311 1.7× 44 0.3× 266 1.9× 171 2.3× 29 690
Simon Briggs New Zealand 12 150 0.5× 67 0.4× 241 1.7× 141 1.0× 234 3.2× 38 645
M Mannazzu Italy 9 155 0.5× 83 0.5× 58 0.4× 97 0.7× 197 2.7× 14 385
Monica Guffanti Italy 11 206 0.6× 143 0.8× 22 0.2× 82 0.6× 158 2.2× 28 349
Laurie Myers United States 8 656 2.1× 454 2.6× 164 1.1× 123 0.9× 533 7.3× 8 899
Daniel Podzamczer Spain 17 500 1.6× 258 1.4× 12 0.1× 343 2.5× 175 2.4× 35 821
Dorella Bricalli Italy 13 430 1.4× 428 2.4× 45 0.3× 173 1.2× 343 4.7× 15 719
Yvonne Higgins United States 15 255 0.8× 83 0.5× 31 0.2× 607 4.3× 126 1.7× 22 907
Juan Flores Spain 9 160 0.5× 31 0.2× 56 0.4× 91 0.7× 42 0.6× 29 326
Anna Danise Italy 13 382 1.2× 289 1.6× 22 0.2× 128 0.9× 104 1.4× 24 504

Countries citing papers authored by Michael Stek

Since Specialization
Citations

This map shows the geographic impact of Michael Stek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Stek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Stek more than expected).

Fields of papers citing papers by Michael Stek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Stek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Stek. The network helps show where Michael Stek may publish in the future.

Co-authorship network of co-authors of Michael Stek

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Stek. A scholar is included among the top collaborators of Michael Stek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Stek. Michael Stek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Maertens, Johan, Gerlinde Egerer, Wan Shik Shin, et al.. (2010). Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry. BMC Infectious Diseases. 10(1). 182–182. 37 indexed citations
2.
Boyd, Mark, Preeyaporn Srasuebkul, Kiat Ruxrungtham, et al.. (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and Genomics. 16(5). 321–329. 43 indexed citations
3.
Boyd, Mark, Preeyaporn Srasuebkul, Kiat Ruxrungtham, et al.. (2006). Boosted versus Unboosted Indinavir with Zidovudine and Lamivudine in Nucleoside Pre-Treated Patients: A Randomized, Open-Label Trial with 112 Weeks of Follow-Up (HIV-Nat 005). Antiviral Therapy. 11(2). 223–232. 14 indexed citations
4.
Casula, Miriam, Gerrit Jan Weverling, Ferdinand W.N.M. Wit, et al.. (2005). Mitochondrial DNA and RNA Increase in Peripheral Blood Mononuclear Cells from HIV‐1–Infected Patients Randomized to Receive Stavudine‐Containing or Stavudine‐Sparing Combination Therapy. The Journal of Infectious Diseases. 192(10). 1794–1800. 36 indexed citations
6.
Porte, Charles la, R.E. Aarnoutse, P.P. Koopmans, et al.. (2005). Pharmacokinetic Interaction Study of Indinavir/Ritonavir and the Enteric‐Coated Capsule Formulation of Didanosine in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(2). 211–218. 6 indexed citations
7.
Aarnoutse, Rob E., Kees Brinkman, Jorge Benetucci, et al.. (2004). Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients. AIDS. 18(3). 565–567. 2 indexed citations
8.
Boyd, Mark, Rob E. Aarnoutse, Kiat Ruxrungtham, et al.. (2003). Pharmacokinetics of Indinavir/Ritonavir (800/100 mg) in Combination With Efavirenz (600 mg) in HIV-1???Infected Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 34(2). 134–139. 21 indexed citations
9.
Burger, David M., Rob E. Aarnoutse, Jeanne P. Dieleman, et al.. (2003). A Once-Daily Haart Regimen Containing Indinavir + Ritonavir plus One Or Two Nucleoside Reverse Transcriptase Inhibitors (Pipo Study). Antiviral Therapy. 8(5). 455–461. 8 indexed citations
10.
Arnaiz, Juan A., Josep Mallolas, Daniel Podzamczer, et al.. (2003). Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 17(6). 831–840. 49 indexed citations
11.
Aarnoutse, Rob E., Denise Telgt, Michael Stek, et al.. (2002). The influence of efavirenz on the pharmacokinetics of a twice‐daily combination of indinavir and low‐dose ritonavir in healthy Volunteers. Clinical Pharmacology & Therapeutics. 71(1). 57–67. 50 indexed citations
12.
Hugen, Patricia W. H., David M. Burger, Hadewych J. M. ter Hofstede, et al.. (2000). Dose-Finding Study of a Once-Daily Indinavir/Ritonavir Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 25(3). 236–245. 19 indexed citations
13.
Hugen, Patricia W. H., David M. Burger, Hadewych J. M. ter Hofstede, et al.. (2000). Dose-Finding Study of a Once-Daily Indinavir/Ritonavir Regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes. 236–245. 7 indexed citations
14.
Weber, David J., et al.. (2000). Experience of Healthcare Workers Taking Postexposure Prophylaxis After Occupational HIV Exposures: Findings of the HIV Postexposure Prophylaxis Registry. Infection Control and Hospital Epidemiology. 21(12). 780–785. 69 indexed citations
15.
Greenspan, Susan L., Mary Bouxsein, Mary E. Melton, et al.. (1997). Precision and Discriminatory Ability of Calcaneal Bone Assessment Technologies. Journal of Bone and Mineral Research. 12(8). 1303–1313. 162 indexed citations
16.
Stek, Michael, et al.. (1981). Attrition of schistosomes in an Irradiation-Attenuated Cercarial Immunization Model of Schistosoma mansoni. American Journal of Tropical Medicine and Hygiene. 30(5). 1033–1038. 9 indexed citations
17.
Hoogstraal, Harry, et al.. (1974). Bahig virus (Tete group) in naturally- and transovarially-infectedHyalomma marginatum ticks from Egypt and Italy. Archives of Virology. 46(1-2). 29–35. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026